Hoth Therapeutics, Inc.: Hoth Therapeutics, Inc. filed a Certificate of Amendment to change its name to 'Rocket One Inc.' effective May 26, 2026, and will start trading under the symbol 'RKTO' on May 28, 2026 (effective 2026-05-26).
“On May 20, 2026, Rocket One Inc. (formerly, Hoth Therapeutics, Inc.) (the “Company”) filed a Certificate of Amendment to its Articles of Incorporation, as amended (the “Charter Amendment”), with the Secretary of State of the State of Nevada to change the name of the Company from “Hoth Therapeutics, Inc.” to “Rocket One Inc.” effective as of May 26, 2026 (the “Name Change”).”
Material Agreements
Hoth Therapeutics, Inc. entered into VCU License Agreements with Virginia Commonwealth University Intellectual Property Foundation (effective 2026-05-15).
“On May 15, 2026 (the "Effective Date"), Rocket One Inc. (“Rocket One”), a newly formed subsidiary of Hoth Therapeutics, Inc. (the “Company”), entered into two exclusive license agreements (collectively, the “VCU License Agreements”) with the Virginia Commonwealth University Intellectual Property Foundation (“VCU”) as further described below.”
Listing & Compliance Notices
Hoth Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“April 30, 2026, Hoth Therapeutics, Inc. (the “Company”) was notified (the “Notification Letter”) by The Nasdaq Stock Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth i”
Equity Issuances
Hoth Therapeutics, Inc. issued warrants to purchase up to an aggregate of 2,857,144 shares of common stock of warrant.
“Additionally, in a concurrent private placement, the Company issued and sold unregistered warrants to purchase up to an aggregate of 2,857,144 shares of common stock at an exercise price of $0.85 per share.”
Equity Issuances
Hoth Therapeutics, Inc. issued 2,857,144 shares of its common stock (or common stock equivalents in lieu thereof) of common stock for $0.70 per share.
“Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering NEW YORK, April 2, 2026 – Hoth Therapeutics, Inc. (Nasdaq: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs, today announced the closing of its previously announced registered direct offering for the purchase and sale of an aggregate of 2,857,144 shares of its common stock (or common stock equivalents in lieu thereof) at an offering price of $0.70 per share of common stock (or per common stock equivalent in lieu thereof).”
Material Agreements
Hoth Therapeutics, Inc. entered into Securities Purchase Agreement with certain institutional investors valued at Company agreed to sell 2,857,144 shares of common stock at $0.70 per share; gross proceeds approxima (effective 2026-04-01).
“On April 1, 2026, Hoth Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors, pursuant to which the Company agreed to sell to such investors 2,857,144 shares (the “Shares”) of common stock of the Company (the “Common Stock”), at a purchase price of $0.70 per share of Common Stock (the “Offering”).”
Listing & Compliance Notices
Hoth Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“May 13, 2025, Hoth Therapeutics, Inc. (the “Company”) was notified (the “Notification Letter”) by The Nasdaq Stock Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Ba”
Graig Springer resigned as Director at Hoth Therapeutics, Inc..
“On April 9, 2025, Graig Springer informed Hoth Therapeutics, Inc. (the “Company”) that he will be resigning from the Company’s Board of Directors (the “Board”) as well as the Company’s audit committee, compensation committee and nominating and corporate governance committee effective as of April 15, 2025.”
Auditor Changes
Hoth Therapeutics, Inc. reported that prior financial statements should not be relied upon.
“the audited consolidated and unaudited condensed consolidated financial statements for each of the Non-Reliance Periods should no longer be relied on.”
Material Agreements
Hoth Therapeutics, Inc. entered into Inducement Letter with a certain holder of existing warrants valued at aggregate gross proceeds of approximately $4.2 million (effective 2024-03-27).
“On March 27, 2024, Hoth Therapeutics, Inc., a Nevada corporation (the “ Company ”), entered into an inducement offer letter agreement (the “ Inducement Letter ”) with a certain holder (the “ Holder ”) of existing warrants (the “ Existing Warrants ”) to purchase shares of common stock of the Company.”
Material Agreements
Hoth Therapeutics, Inc. entered into Purchase Agreement with certain institutional investors valued at $2.89 million (effective 2023-09-13).
“On September 13, 2023, Hoth Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors, pursuant to which the Company agreed to sell to such investors 549,275 shares (the “Shares”) of common stock of the Company (the “Common Stock”), pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 550,725 shares of Common Stock of the Company (the “Pre-Funded Warrant Shares”), having an exercise price of $0.001 per share, at a purchase price of $2.63 per share of Common Stock and a purchase price of $2.629 per Pre-Funded Warrant (the “Offering”).”
Shareholder Votes
Hoth Therapeutics, Inc. shareholders approved Approval of Hoth Therapeutics, Inc. Amended and Restated 2022 Omnibus Equity Incentive Plan at the 2023-08-18 meeting.
“The shareholders approved the Amended and Restated 2022 Plan. The result of the votes to approve the Amended and Restated 2022 Plan was as follows: For Against Abstain Broker Non-Votes 190,903 112,224 27,459 993,489”
Shareholder Votes
Hoth Therapeutics, Inc. shareholders approved Ratification of appointment of Withum Smith+Brown, PC as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-08-18 meeting.
“The shareholders approved the ratification of the appointment of Withum as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The result of the votes to approve Withum was as follows: For Against Abstain 1,111,058 158,230 54,787”
Shareholder Votes
Hoth Therapeutics, Inc. shareholders approved Election of five directors to serve until the next annual meeting at the 2023-08-18 meeting.
“All of the five nominees for director were elected to serve until the next annual meeting of shareholders or until their respective successors have been duly elected and qualified, or until such director’s earlier resignation, removal or death. The result of the votes to elect the five directors were as follows: Directors For Against Abstentions Broker Non-Votes Robb Knie 220,147 58,177 52,262 993,489 David Sarnoff 217,637 57,613 55,336 993,489 Graig Springer 199,778 78,545 52,263 993,489 Wayne Linsley 207,197 70,970 52,419 993,489 Jeff Pavell 213,588 63,044 53,954 993,489”
Material Agreements
Hoth Therapeutics, Inc. entered into Purchase Agreement with an accredited investor valued at aggregate gross proceeds of approximately $10 million (effective 2022-12-29).
“On December 29, 2022, Hoth Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an accredited investor (the “Investor”) pursuant to which it agreed to sell an aggregate of (i) 140,000 shares (the “Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), (ii) warrants (the “Pre-Funded Warrants”) to purchase up to 1,860,000 shares (the “Pre-funded Warrant Shares”) of Common Stock and (iii) warrants (the “Common Stock Warrants” and together with the Pre-Funded Warrants, the “Warrants”) to purchase up to 2,500,000 shares (the “Warrant Shares” and together with the Shares and the Pre-Funded Warrant Shares, the “Registrable Securities”) of Common Stock at a purchase price of $5.00 per share and accompanying warrant (less $0.001 for each Pre-Funded Warrant and accompanying warrant) in a private placement for aggregate gross proceeds of approximately $10 million, exclusive of placement agent commission and fees and o”
“On December 13, 2022, the Company filed a Certificate of Amendment (the “Amendment”) to its Articles of Incorporation, as amended, to increase its authorized shares of common stock from 3,000,000 shares to 50,000,000 shares.”
Shareholder Votes
Hoth Therapeutics, Inc. shareholders approved increase to the number of authorized shares of the Company’s common stock from 3,000,000 shares to 50,000,000 shares at the 2022-12-12 meeting.
“On December 12, 2022, the Company held its 2022 special meeting of shareholders (the “Special Meeting”) for the purpose holding a shareholder vote on Proposal 1 set forth below. A total of 551,003 shares of the Company’s common stock and 2,000,000 shares of the Company’s Series B Preferred Stock, constituting a quorum, were represented in person or by valid proxies at the Special Meeting. As previously described in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on November 14, 2022 (the “Proxy Statement”), the holder of record of the 2,000,000 outstanding shares of the Company’s Series B Preferred Stock was entitled to 20,000,000 votes, had the right to vote only on Proposal 1, and such votes were counted in the same proportion as the shares of the Company’s common stock voted on Proposal 1. Holders of the Company’s common stock were entitled to one vote per share on Proposal 1. Proposal 1 . At the Special Meeting, the shareholders approved a”
Stefanie Johns was appointed as Scientific Advisory Board member at Hoth Therapeutics, Inc..
“On December 12, 2022, Dr. Johns joined the Company’s Scientific Advisory Board and will continue to consult and monitor the Company’s pipeline development in such role.”
Stefanie Johns departed as Chief Scientific Officer at Hoth Therapeutics, Inc..
“On December 9, 2022 (the “Separation Date”), the employment of Stefanie Johns as Chief Scientific Officer of the Company ceased.”
Jeff Pavell was appointed as member of the Board at Hoth Therapeutics, Inc..
“On December 7, 2022, the board of directors (the “Board”) of Hoth Therapeutics, Inc. (the “Company”) increased the size of the Board to five members and appointed Jeff Pavell, D.O., as a member of the Board to fill the vacancy created by the increase in the size of the Board.”
Governance Changes
Hoth Therapeutics, Inc.: Created Series B Preferred Stock, designating 2,000,000 shares (effective 2022-11-02).
“On November 2, 2022, the Company filed a Certificate of Designation of the Series B Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Nevada to create a new class of Series B Preferred Stock, par value $0.0001 per share.”
Material Agreements
Hoth Therapeutics, Inc. entered into Subscription Agreement with an investor valued at $1,000 (effective 2022-11-02).
“On November 2, 2022, Hoth Therapeutics, Inc. (the “Company”) entered into a Subscription and Investment Representation Agreement (the “Subscription Agreement”) with an investor (the “Purchaser”) pursuant to which it issued and sold 2,000,000 shares (the “Shares”) of the Company’s newly designated Series B Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock”), to such Purchaser for an aggregate purchase price of $1,000.”
Vadim Mats departed as Director at Hoth Therapeutics, Inc..
“On January 19, 2022, Vadim Mats informed Hoth Therapeutics, Inc. (the “Company”) that he will be resigning from the Company’s Board of Directors (the “Board”) as well as the Company’s compensation committee and nominating and corporate governance committee effective as of January 31, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.